{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"177-427-178-174-019","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"177-427-178-174-019","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11761,"type":"PATENT","title":"Dartmouth College Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2493,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8400,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: Dartmouth colle*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2346
Search Applicants and Owners separately: Dartmouth colle*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2346
(i) is modified to functionally impair or to reduce expression of the endogenous T cell receptor (TCR), and\n
(ii) is further modified to express at least one functional exogenous non-TCR that comprises a chimeric receptor comprising a ligand binding domain attached to a signaling domain,\nwherein said modified primary human T cell is suitable for use in human therapy, and further wherein the isolated primary human T cell modified as in (i) and (ii) elicits no or a reduced graft-versus-host disease (GVHD) response in a histoincompatible human recipient as compared to the GVHD response elicited by a primary human T cell isolated from the same human donor that is only modified as in (ii)."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, wherein the chimeric receptor comprises a NKG2D, NKG2A, NKG2C, NKG2F, LLT1, AICL, CD26, or NKRP1 polypeptide."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, wherein the ligand binding domain is obtained from an anti-tumor chimeric antigen receptor or anti-tumor antibody."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, wherein the chimeric receptor comprises a receptor that binds to MIC-A, MIC-B, estrogen, progesterone, RON, or one or more members of the ULBP/RAET1 family."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 4, wherein the one or more members of the ULBP/RAET1 family is/are selected from ULBP2, ULBP3, Rae-1, H-60, HCMV UL18, or Rae-1β."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, wherein the ligand binding domain comprises a pathogen-associated receptor and wherein the T cell can be used to treat infectious disease."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 6, wherein the infectious disease to be treated is caused by a CMV, HIV-1, HIV-2, HBV, HCV or a hantavirus infection."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A composition suitable for use in human therapy, comprising a therapeutically effective amount of isolated modified primary human T cells according to claim 1 and at least one pharmaceutically acceptable carrier."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, wherein the ligand binding domain is a NKG2D ligand binding domain, and the signaling domain is a CD3 £ signaling domain."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, which is derived from an allogeneic T cell or primary human PBMCs isolated from a human subject."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, wherein the T cell expresses CD4 or CD8."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["An isolated modified primary human T cell, which is derived from a primary human T cell isolated from a human donor, that:\n
(i) is modified to functionally impair or to reduce expression of the endogenous T cell receptor (TCR), and\n
(ii) is further modified to express at least one functional exogenous non-TCR that comprises a chimeric receptor comprising a NKG2D ligand binding domain attached to a CD3 £ signaling domain,\nwherein said modified primary human T cell is suitable for use in human therapy, and further wherein the isolated primary human T cell modified as in (i) and (ii) elicits no or a reduced GVHD response in a histoincompatible human recipient as compared to the GVHD response elicited by a primary human T cell isolated from the same human donor that is only modified as in (ii)."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, which is capable of differentiating into a T regulatory cell."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, wherein the reduced GVHD response is evidenced by the isolated primary human T cell modified as in (i) and (ii) eliciting reduced expression of gamma interferon as compared to a primary human T cell isolated from the same human donor that is only modified as in (ii)."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, wherein the reduced GVHD response is evidenced by the isolated primary human T cell modified as in (i) and (ii) not eliciting an increase in expression of gamma interferon as compared to a primary human T cell isolated from the same human donor that is only modified as in (ii)."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, wherein the isolated primary human T cell modified as in (i) and (ii) does not elicit a GVHD response in a human recipient."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, wherein the chimeric receptor comprises a chimeric natural killer (NK) cell receptor."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 1, wherein the chimeric receptor binds to tumor cells."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 12, wherein the isolated primary human T cell modified as in (i) and (ii) does not elicit a GVHD response in a human recipient."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 12, wherein the reduced GVHD response is evidenced by the isolated primary human T cell modified as in (i) and (ii) eliciting reduced expression of gamma interferon as compared to a primary human T cell isolated from the same donor that is only modified as in (ii)."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The isolated modified primary human T cell of claim 12, wherein the reduced GVHD response is evidenced by the isolated primary human T cell modified as in (i) and (ii) not eliciting an increase in expression of gamma interferon as compared to a primary human T cell isolated from the same donor that is only modified as in (ii)."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["A composition suitable for use in human therapy, comprising a therapeutically effective amount of isolated modified primary human T cells according to claim 12 and at least one pharmaceutically acceptable carrier."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["A composition suitable for use in human therapy, comprising a therapeutically effective amount of isolated modified primary human T cells according to claim 17 and at least one pharmaceutically acceptable carrier."],"number":23,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}